Tag: Eli Lilly

BI and Eli Lilly Announced Detailed Findings from the CAROLINA® Trials

Boehringer Ingelheim and Eli Lilly and Company announced detailed findings from the CAROLINA® trial demonstrating that Tradjenta® (linagliptin) did not increase cardiovascular risk compared with glime...

FDA Accepted Boehringer, Lilly NDA for Triple Combination Tablet for Adults with Type 2 Diabetes

diabetes drugs
The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for the investigational fixed-dose combination tablet of empagliflozin, linagliptin and metformin extended relea...

FDA Approved Eli Lilly’s Emgality

The U.S. Food and Drug Administration approved Emgality (galcanezumab-gnlm) solution for injection for the treatment of episodic cluster headache in adults.  “Emgality provides patients with the firs...

Lilly’s Insulin Lispro Injection List Price Announced

Eli Lilly and Company's Insulin Lispro Injection is now available for order in pharmacies for people who use Lilly's rapid-acting insulin and need a lower-cost option. Lilly's Insulin Lispro Injection...

FDA Approved Eli Lilly Cyramza for Hepatocellular Carcinoma

lilly
On May 10, 2019, the Food and Drug Administration approved ramucirumab (CYRAMZA®, Eli Lilly and Company) as a single agent for hepatocellular carcinoma (HCC) in patients who have an alpha fetoprotein ...

Eli Lilly Q1 Profit Tripled

Eli Lilly and Co reported lower-than-expected sales for its top-selling diabetes drug Trulicity and cut its full-year revenue forecast as it sees further hits from price declines in the United States,...

Eli Lilly Selling Chinese Rights to Two Legacy Antibiotics

Eli Lilly has inked a $375 million deal with China-based Eddingpharm for the rights to two legacy antibiotic medicines and manufacturing facility in Suzhou, China. The sale of off-patent drug asset...

Prozac to Withdraw from Taiwan in April

The popular antidepressant Prozac is to be permanently removed from pharmacy shelves this April in Taiwan, announced the drug's Taiwanese manufacturer Zuellig Pharma (裕利藥廠) last week, reported CNA. ...

Priority Review for Lilly’s Preventing Cluster Headache Injection

Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for its supplemental Biologics License Application (sBLA) for Emgality® (galcanezumab...

Lilly Launches Low-Priced Insulin

Authorized generic version of Humalog will be available in U.S. pharmacies at 50 percent lower list price. Reinforcing the commitment to lower out-of-pocket costs for people who need insulin, Eli L...

Positive Top-Line Results of Pfizer and Lilly’s Drug Phase 3

Pfizer Inc. and Eli Lilly and Company today announced positive top-line results from a Phase 3 study evaluating tanezumab in patients with moderate-to-severe chronic low back pain (CLBP). In the study...

Bayer to Obtain Full Rights on Two Loxo’s Drugs

Bayer exercised option under change-in-control clause in it’s agreement with Loxo Oncology to obtain full licensing rights for the two TRK inhibitor agents. Bayer has exercised its option, under a ...

Eli Lilly Successfully Acquired Loxo Oncology

Eli Lilly and Company today announced the successful completion of its acquisition of Loxo Oncology, Inc. The acquisition broadens the scope of Lilly's oncology portfolio into precision medicines thro...

Boehringer and Lilly’s 2 Diabetes Drug Met Endpoint

Boehringer Ingelheim and Eli Lilly and Company announced CAROLINA® (CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with type 2 diabetes) met its primary endpoint, defined a...

Drug Giants Should Explain High Prices on Insulin

Sanofi, Eli Lilly and Novo Nordisk have been sent letters by US lawmakers requesting information on the increased costs of insulin in recent years and the companies’ profit from sales of these product...

CVS Added Teva and Lilly’s Drugs, Excluding Amgen’s

CVS Health Corp, a top U.S. manager of pharmacy benefits, has added new migraine drugs from Teva Pharmaceutical Industries and Eli Lilly and Co to its list of covered drugs, excluding a rival treatmen...